The FDA has granted approval for the use of Spravato nasal spray, developed by Johnson & Johnson (JNJ.US), for the treatment of adult patients suffering from treatment-resistant depression (TRD).
Tuesday, Jan 21, 2025 8:21 pm ET
1min read Johnson & Johnson (JNJ.US) announced on January 21 that the FDA has approved its Spravato (esketamine) nasal spray for the treatment of adults with treatment-resistant depression (TRD). The trial showed that Spravato reached the primary endpoint at week 4. It also showed a rapid and significant improvement in depressive symptoms compared to placebo as early as 24 hours. According to the press release, Spravato is the first single-agent therapy approved for the treatment of adult depression (MDD) patients who have not adequately responded to at least two oral antidepressants.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
_219eac971750077834984.jpeg)
